Study Detail
If you join a clinical trial with us, you’ll receive patient-centered care and open communication during the study and beyond. Your comfort is our priority.
Sanofi Study for nrSPMS
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sanofi’s FREVIVA Study is looking for people with non-relapsing secondary progressive multiple sclerosis (nrSPMS) to take part. The goal of this Phase 3 clinical trial is to demonstrate the efficacy and safety of frexalimab compared to placebo in participants with nrSPMS to delay disability progression.
Additional Study Details
This study will have variable duration ranging from approximately 27 to 51 months, depending on enrollment date.
The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
Participants will receive a stipend for each visit as well as travel reimbursement.
Who can take part in the study?
Individuals 18-60 years old
Individuals with a previous diagnosis of RRMS
Individuals with a current diagnosis of SPMS with documented disability progression within the past 12 months
Individuals with an EDSS of 3.0 - 6.0
Individuals with an absence of relapses in the past 24 months
